Ikaria plots $200M IPO

Undaunted by the lower-than-expected debuts of other biotech IPOs, Ikaria has filed for a $200 million IPO. The New Jersey-based company, which also has R&D operations in Seattle, plans to trade on NASDAQ under ticker symbol IKAR.

Unlike most biotechs, Ikaria actually generates revenue through its INOtherapy program, which includes INOMAX, the only FDA-approved treatment for hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. The company reports nearly $275 million in 2009 revenue, and its net income grew from $9.6 million to $13 million.

On the R&D side of the business, Ikaria has two late-stage product candidates and a number in earlier clinical or preclinical development. The most intriguing candidate in its pipeline is IK-1001, which Xconomy describes as "something from a science fiction novel." The hibernation drug slows down a patient's heartbeat and breathing in order to give physicians time to save that patient in an emergency situation. The therapy is in Phase II trials.

- see the SEC filing
- here's the Xconomy report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.